Alpha 2.0
Login Register
» Articles » PMID: 39456530

Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Oct 26
PMID 39456530
Authors
Andres Bravo-Gonzalez
Maryam Alasfour
Deborah Soong
Jose Noy
Georgios Pongas
Affiliations
Soon will be listed here.
Abstract

B-cell lymphoid malignancies are a heterogeneous group of hematologic cancers, where Bruton's tyrosine kinase (BTK) inhibitors have received FDA approval for several subtypes. The first-in-class covalent BTK inhibitor, Ibrutinib, binds to the C481 amino acid residue to block the BTK enzyme and prevent the downstream signaling. Resistance to covalent BTK inhibitors (BTKi) can occur through mutations at the BTK binding site (C481S) but also other BTK sites and the phospholipase C gamma 2 (PLCγ2) resulting in downstream signaling. To bypass the C481S mutation, non-covalent BTKi, such as Pirtobrutinib, were developed and are active against both wild-type and the C481S mutation. In this review, we discuss the molecular and genetic mechanisms which contribute to acquisition of resistance to covalent and non-covalent BTKi. In addition, we discuss the new emerging class of BTK degraders, which utilize the evolution of proteolysis-targeting chimeras (PROTACs) to degrade the BTK protein and constitute an important avenue of overcoming resistance. The moving landscape of resistance to BTKi and the development of new therapeutic strategies highlight the ongoing advances being made towards the pursuit of a cure for B-cell lymphoid malignancies.

References
1.
Quinquenel A, Fornecker L, Letestu R, Ysebaert L, Fleury C, Lazarian G . Prevalence of and mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 2019; 134(7):641-644. DOI: 10.1182/blood.2019000854. View
2.
Honigberg L, Smith A, Sirisawad M, Verner E, Loury D, Chang B . The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010; 107(29):13075-80. PMC: 2919935. DOI: 10.1073/pnas.1004594107. View
3.
Mato A, Shah N, Jurczak W, Cheah C, Pagel J, Woyach J . Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021; 397(10277):892-901. PMC: 11758240. DOI: 10.1016/S0140-6736(21)00224-5. View
4.
Lam K, Kuhn R, Rajewsky K . In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997; 90(6):1073-83. DOI: 10.1016/s0092-8674(00)80373-6. View
5.
Robbins D, Noviski M, Tan Y, Konst Z, Kelly A, Auger P . Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. J Med Chem. 2024; 67(4):2321-2336. DOI: 10.1021/acs.jmedchem.3c01007. View